Wave Life Sciences Ltd (WVE) Shares Have Inclined 194.85% Year To Date

Wave Life Sciences Ltd (NASDAQ:WVE) has a beta value of -1.24 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $2.26B, closed the last trade at $14.89 per share which meant it gained $0.62 on the day or 4.34% during that session. The WVE stock price is -12.42% off its 52-week high price of $16.74 and 76.49% above the 52-week low of $3.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.28 million shares traded. The 3-month trading volume is 1.80 million shares.

The consensus among analysts is that Wave Life Sciences Ltd (WVE) is Buy stock at the moment, with a recommendation rating of 1.20. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.24.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Wave Life Sciences Ltd (NASDAQ:WVE) trade information

Sporting 4.34% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the WVE stock price touched $14.89 or saw a rise of 1.33%. Year-to-date, Wave Life Sciences Ltd shares have moved 194.85%, while the 5-day performance has seen it change 15.88%. Over the past 30 days, the shares of Wave Life Sciences Ltd (NASDAQ:WVE) have changed 3.04%. Short interest in the company has seen 6.82 million shares shorted with days to cover at 3.38.

Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 32.32% from current levels. The projected low price target is $15.0 while the price target rests at a high of $36.0. In that case, then, we find that the current price level is -141.77% off the targeted high while a plunge would see the stock gain -0.74% from current levels.

Wave Life Sciences Ltd (WVE) estimates and forecasts

Figures show that Wave Life Sciences Ltd shares have underperformed across the wider relevant industry. The company’s shares have gained 142.51% over the past 6 months, with this year growth rate of -111.11%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be -54.94%.

9 analysts offering their estimates for the company have set an average revenue estimate of 25.59M for the current quarter. 5 have an estimated revenue figure of 12.8M for the next ending quarter. Year-ago sales stood 29.06M and 12.54M respectively for this quarter and the next, and analysts expect sales will shrink by -11.91% for the current quarter and -54.94% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 36.03% over the past 5 years.

WVE Dividends

Wave Life Sciences Ltd is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Wave Life Sciences Ltd (NASDAQ:WVE)’s Major holders

Insiders own 15.04% of the company shares, while shares held by institutions stand at 78.49% with a share float percentage of 92.38%. Investors are also buoyed by the number of investors in a company, with Wave Life Sciences Ltd having a total of 215.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 18.2 million shares worth more than $90.83 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 14.0527% of shares outstanding.

The other major institutional holder is MAVERICK CAPITAL LTD, with the holding of over 7.67 million shares as of 2024-06-30. The firm’s total holdings are worth over $38.27 million and represent 5.9211% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Primecap Odyssey Aggressive Growth Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 1.66% shares in the company for having 2.52 shares of worth $37.59 million while later fund manager owns 2.02 shares of worth $30.05 million as of Sep 30, 2024 , which makes it owner of about 1.32% of company’s outstanding stock.